Contraceptive Methods Overview
Efficacy is expressed as the Pearl Index — pregnancies per 100 woman-years of use. Perfect use reflects consistent, correct use; typical use reflects real-world conditions including user error.
Efficacy Comparison Table
| Method | Category | Typical Use Failure %/yr | Perfect Use Failure %/yr | Duration | Notes |
|---|---|---|---|---|---|
| Copper IUD | LARC | <1% | <1% | Up to 10 yr | No hormones; best EC method |
| LNG-IUS (Mirena) | LARC | <1% | <1% | 5–8 yr | Reduces HMB; amenorrhoea common |
| Implant (Nexplanon) | LARC | <1% | <1% | 3 yr | No user action; irregular bleeding |
| DMPA (Depo-Provera) | LARC | 4% | <1% | 12 wk | Requires clinic visit; fertility delay |
| COC (combined pill) | Hormonal | 9% | <1% | Daily | Non-contraceptive benefits; UKMEC limits |
| Patch (Evra) | Hormonal | 9% | <1% | Weekly x3 | Higher EE dose; avoid if >90 kg |
| Vaginal Ring (NuvaRing) | Hormonal | 9% | <1% | Monthly | User-inserted; same UKMEC as COC |
| POP (progestogen-only pill) | PO | 9% | <1% | Daily (3h window) | Desogestrel POP: 12h window |
| Male condom | Barrier | 15% | 2% | Single use | Only method preventing STIs |
| Female condom | Barrier | 21% | 5% | Single use | Female-controlled; latex-free |
| Diaphragm + spermicide | Barrier | 12–17% | 6% | Reusable | Requires fitting; no STI protection |
| Fertility Awareness | Natural | 24% | 1–5% | — | Multiple methods; requires training |
| Levonorgestrel EC | Emergency | 84% efficacy (within 72h) | Single dose | Not for regular use | |
| UPA EC (ellaOne) | Emergency | Superior at 72–120h | Single dose | Avoid with enzyme inducers | |
| Female sterilisation | Permanent | <1% | <1% | Permanent | Ectopic pregnancy risk if fails |
| Vasectomy | Permanent | <1% | <1% | Permanent | Simpler procedure; confirm azoospermia |
LARC — Long-Acting Reversible Contraception
Efficacy: >99% — most cost-effective methods over time. Includes:
- Copper IUD — non-hormonal, 10 years
- LNG-IUS (Mirena/Kyleena) — 5–8 years
- Nexplanon implant — 3 years, subdermal
- DMPA (Depo-Provera) — 12-weekly injection
Efficacy >99%
Combined Hormonal Contraception
Typical: 91% | Perfect: >99%. Contains oestrogen + progestogen. Forms:
- COC (combined oral contraceptive)
- Transdermal patch (Evra — weekly)
- Vaginal ring (NuvaRing — monthly)
Non-contraceptive benefits: regulates cycle, reduces dysmenorrhoea, treats acne, HMB, endometriosis.
Typical use efficacy 91%
Progestogen-Only Methods
- POP: daily pill, 3h window (desogestrel 12h). Suitable for breastfeeding, HTN, migraine with aura
- Implant: Nexplanon — set-and-forget 3 years
- DMPA: 150mg IM every 12 weeks. Bone density consideration >2 years
Barrier & Natural Methods
- Male condom: 85% typical / 98% perfect use — dual protection (STI + pregnancy)
- Female condom: 79% typical / 95% perfect
- Diaphragm/cap: requires fitting + spermicide
- FAM (fertility awareness): 76–99% depending on method and adherence
Emergency Contraception — Overview
Levonorgestrel 1.5mg (Levonelle)
- Within 72 hours
- Efficacy ~84% (reduces with time)
- Safe while breastfeeding
Ulipristal acetate 30mg (ellaOne)
- Within 120 hours
- Superior efficacy at 72–120h
- Avoid in severe asthma on glucocorticoids
Copper IUD
- Within 120 hours (5 days)
- Efficacy >99%
- Provides ongoing contraception
UKMEC / WHO Medical Eligibility Criteria
The UK Medical Eligibility Criteria (UKMEC) is adapted from WHO MEC. Each condition is assigned a category for each contraceptive method.
1
No restriction
Method can be used without restriction. Condition does not affect eligibility.
2
Advantages outweigh risks
Method can generally be used. Benefits outweigh theoretical or proven risks.
3
Risks outweigh advantages
Method not usually recommended unless no other method acceptable. Clinical judgement required.
4
Unacceptable health risk
Method should NOT be used. Condition represents an unacceptable health risk.
Key Principle
UKMEC 3 & 4 are relative/absolute contraindications. Always document clinical reasoning when prescribing outside category 1–2.
UKMEC 4 = absolute contraindication. Do not prescribe.
UKMEC 1 or 2 = safe to use with the condition present.
Exam Tip
Combined methods (COC/patch/ring) share identical UKMEC categories. When a question lists one, apply the same rule to all three.
Key Conditions — UKMEC Category Reference Table
| Condition | Combined (COC/Patch/Ring) | POP | Implant | DMPA | Cu-IUD | LNG-IUS |
|---|---|---|---|---|---|---|
| Hypertension 140–159 / 90–99 | 3 | 1 | 1 | 2 | 1 | 1 |
| Hypertension ≥160 / 100 | 4 | 1 | 1 | 3 | 1 | 1 |
| Migraine WITH aura | 4 | 2 | 2 | 2 | 1 | 2 |
| Migraine without aura | 2 | 1 | 1 | 1 | 1 | 1 |
| DVT / PE — history | 4 | 2 | 2 | 2 | 1 | 2 |
| Breastfeeding <6 weeks post-partum | 4 | 2 | 2 | 2 | 1 | 2 |
| Breastfeeding 6 wk – 6 months | 3 | 1 | 1 | 1 | 1 | 1 |
| Smoking ≥35 yrs, <15 cig/day | 3 | 1 | 1 | 1 | 1 | 1 |
| Smoking ≥35 yrs, ≥15 cig/day | 4 | 1 | 1 | 1 | 1 | 1 |
| Severe liver disease / cirrhosis | 4 | 3 | 3 | 3 | 1 | 3 |
| SLE — positive antiphospholipid Ab | 4 | 3 | 3 | 3 | 2 | 3 |
| Diabetes with vascular disease | 3–4 | 2 | 2 | 2 | 1 | 2 |
| Unexplained vaginal bleeding | 2 | 2 | 3 | 3 | 4 | 4 |
| Current breast cancer | 4 | 4 | 4 | 4 | 1 | 4 |
ABSOLUTE CONTRAINDICATIONS to combined hormonal methods: migraine with aura, DVT/PE history, BP ≥160/100, breast cancer, severe liver disease, antiphospholipid syndrome, smoking ≥35 years with ≥15 cigarettes/day, <6 weeks post-partum breastfeeding.
LARC Methods — In-Depth Clinical Reference
Long-acting reversible contraceptives are the most effective reversible methods available. Efficacy >99% is independent of user compliance.
Mirena LNG-IUS (Levonorgestrel Intrauterine System)
52mg LNG
5–8 Years
Primary: HMB + Contraception
- Releases ~20 mcg LNG/day locally — minimal systemic absorption
- Thickens cervical mucus; suppresses endometrium
- Bleeding pattern: irregular 3–6 months → amenorrhoea in ~80% by 1 year
- Licensed for HMB, dysmenorrhoea, endometriosis, HRT endometrial protection
- Suitable for nulliparous women (smaller Kyleena available)
- Return to fertility: immediate on removal
- Insertion: within 7 days of period, post-partum after 4 weeks
Progestogenic side effects: breast tenderness, acne, mood changes — usually resolve as systemic levels are low.
Copper IUD (Intrauterine Device)
Non-Hormonal
Up to 10 Years
Best EC Method
- Copper ions toxic to sperm; primary mechanism spermicidal
- No systemic hormonal effects — suitable for oestrogen-sensitive conditions
- Bleeding: heavier, more prolonged periods — main reason for discontinuation
- Most effective EC: inserted within 120h post-UPSI (unprotected sexual intercourse), efficacy >99%
- Can be inserted up to 5 days after earliest expected ovulation
- Contraindication: unexplained vaginal bleeding, uterine cavity distortion, current PID
- Return to fertility: immediate on removal
Ectopic pregnancy: if pregnancy occurs with IUD in situ, increased risk of ectopic — refer urgently.
Nexplanon Implant (Etonogestrel)
3 Years
4cm Subdermal Rod
No User Action
- Single flexible rod inserted subdermally in non-dominant upper arm
- Releases ~60–70 mcg etonogestrel/day, reducing over time
- Primary mechanism: inhibits ovulation (highly reliable)
- Main side effect: irregular/unpredictable bleeding — counsel before insertion
- Amenorrhoea in ~20%, prolonged bleeding ~20%, infrequent ~30%, normal ~30%
- No weight limit contraindication (unlike older advice)
- Contains barium sulphate — visible on X-ray if impalpable
- Return to fertility: within days of removal
- Insertion/removal: trained healthcare professional only
Enzyme inducers (rifampicin, carbamazepine, phenytoin) reduce implant efficacy — consider Cu-IUD.
DMPA — Depo-Provera (Depot Medroxyprogesterone Acetate)
150mg IM
Every 12 Weeks
Fertility Delay
- Deep IM injection deltoid or gluteal; also Sayana Press (SC 104mg) — self-injectable
- Inhibits ovulation, thickens cervical mucus
- Amenorrhoea: ~70% after 1 year of use
- Return of fertility: delayed 6–12 months after last injection (can be up to 24 months)
- Bone density: reversible reduction — DEXA scan if use >2 years; counsel adolescents and perimenopausal women
- Repeat injection: every 12 weeks ±2 weeks (up to 14 weeks accepted)
- Late injection (>14 weeks): exclude pregnancy, use barrier 7 days
- Suitable for women who can't use oestrogen; not ideal if immediate fertility desired
Bone density loss is reversible after stopping DMPA. Additional calcium/vitamin D may be recommended for prolonged users.
LARC Comparison Summary
| Feature | Mirena IUS | Copper IUD | Nexplanon | DMPA |
|---|---|---|---|---|
| Duration | 5–8 yr | 10 yr | 3 yr | 12 wk |
| Hormonal | Yes (local LNG) | No | Yes (ENG) | Yes (DMPA) |
| Typical bleeding effect | Reduced → amenorrhoea | Heavier | Unpredictable | Amenorrhoea 70% |
| Immediate fertility return | Yes | Yes | Yes (days) | No (6–12+ months) |
| Use as EC | No | Yes | No | No |
| UKMEC migraine with aura | 2 | 1 | 2 | 2 |
| UKMEC DVT history | 2 | 1 | 2 | 2 |
Emergency Contraception & Special Situations
Emergency contraception (EC) prevents pregnancy after unprotected sexual intercourse (UPSI) or contraceptive failure. It is NOT abortifacient.
Levonorgestrel (Levonelle 1.5mg)
- Window: Within 72 hours of UPSI
- Efficacy: ~84% overall; declines with time (~95% day 1, ~58% day 3)
- Mechanism: delays/inhibits ovulation
- Safe while breastfeeding (no clinically significant transfer)
- No absolute contraindications (UKMEC 2 for most conditions)
- Enzyme inducers reduce efficacy — double dose (3mg) or use Cu-IUD
- If BMI >26 or weight >70kg — reduced efficacy; prefer UPA or Cu-IUD
- Can be obtained OTC without prescription
Ulipristal Acetate (ellaOne 30mg)
- Window: Within 120 hours (5 days) of UPSI
- Superior to LNG at 72–120h interval
- Selective progesterone receptor modulator (SPRM)
- Avoid with breastfeeding: express and discard milk for 1 week after dose
- Avoid with enzyme inducers (reduces UPA efficacy)
- Avoid with regular progesterone contraception (mutual interference) — restart after 5 days
- Prescription only in most countries
- Severe hepatic impairment: avoid
Copper IUD — EC
- Most effective EC: >99% efficacy
- Insert within 120h (5 days) of UPSI, OR within 5 days of earliest expected ovulation
- No weight/BMI limitation
- Provides ongoing contraception for up to 10 years
- Suitable even if enzyme inducer use
- Screen for STIs at insertion (or treat empirically if high risk)
- Suitable for most women — check UKMEC for specific conditions
Quick Start — Starting Contraception at Any Time
Quick Start means initiating regular contraception immediately rather than waiting for the next period, provided pregnancy is reasonably excluded.
- Exclude pregnancy: last period, recent UPSI timing, symptoms; perform BHCG if indicated
- Start COC/POP/implant/IUS any day — use condoms for 7 days (2 days for desogestrel POP)
- Copper IUD: immediate — no additional contraception needed
- Advise pregnancy test in 3 weeks if any uncertainty
- Document counselling and patient consent to Quick Start
Quick Start is endorsed by FSRH (Faculty of Sexual and Reproductive Healthcare) guidance to reduce unplanned pregnancy from delayed initiation.
Drug Interactions — Enzyme Inducers
Enzyme-inducing drugs accelerate hepatic metabolism of hormonal contraceptives, reducing plasma levels and efficacy.
| Drug Class | Examples | Effect on Contraception | Recommended Action |
|---|---|---|---|
| Antiepileptics | Carbamazepine, phenytoin, phenobarbital, topiramate (>200mg/d), oxcarbazepine | Reduces all hormonal efficacy | Use Cu-IUD or LNG-IUS; avoid hormonal methods |
| Antibiotics | Rifampicin, rifabutin | Significant reduction (most potent enzyme inducer) | Cu-IUD preferred; if hormonal: use barrier + continue 28d after stop |
| Antiretrovirals | Ritonavir-boosted regimens, efavirenz | Variable — some reduce, some increase hormone levels | Check individual ARV; Cu-IUD or LNG-IUS safest |
| Herbal | St John's Wort | Reduces hormonal efficacy | Avoid with hormonal contraception or use barrier |
Post-Partum Contraception Timing
| Method | Breastfeeding | Not Breastfeeding | Notes |
|---|---|---|---|
| COC/Patch/Ring | Avoid <6 months (UKMEC 3–4) | From day 21 | VTE risk elevated post-partum |
| POP | Immediately post-delivery | From day 21 | Safe in breastfeeding |
| Implant | Immediately | Immediately | Preferred LARC post-partum |
| DMPA | After 6 weeks | After 6 weeks (or day 21 non-BF) | Bone density; fertility delay counselling |
| LNG-IUS / Cu-IUD | After 4 weeks | After 4 weeks | Can insert at C-section (immediate post-placental) |
LAM (Lactational Amenorrhoea Method): >98% effective if fully breastfeeding, <6 months post-partum, and amenorrhoeic — all three conditions must be met.
Sexual Health Integration
Comprehensive sexual and reproductive healthcare integrates contraception with STI prevention, screening, vaccination, and broader wellbeing.
Dual Protection Concept
Dual protection means simultaneously preventing both pregnancy and STIs.
- Condoms (male/female) are the ONLY contraceptive method that prevent STIs
- Recommend condoms PLUS a highly effective contraceptive (ideally LARC)
- Especially important: new partners, multiple partners, STI history, post-EC
- Counsel: consistent correct condom use essential even with LARC in place
Key nursing message: LARC prevents pregnancy; condom prevents STIs. Both needed for complete protection.
STI Screening & LARC Insertion
- Screen for chlamydia and gonorrhoea before/at IUD/IUS insertion
- If high risk and results awaited: insertion can proceed with empirical antibiotic cover (azithromycin 1g) in some guidelines
- Pelvic inflammatory disease (PID): UKMEC 4 for IUD/IUS insertion if current PID
- Post-insertion PID risk: elevated in first 20 days; thereafter returns to background rate
- Partner notification: chlamydia/gonorrhoea — inform and treat sexual contacts
- Cervical screening: remind patients; contraceptive consultation is an opportunity
HPV & Vaccination
- HPV vaccination (Gardasil 9): prevents strains 6, 11, 16, 18, 31, 33, 45, 52, 58
- GCC schedules: typically offered age 9–14 girls; some programmes include boys
- Vaccination does not replace cervical screening
- Catch-up vaccination up to age 26 (and selected adults to 45)
- Contraception consultation: opportunity to discuss vaccination status
Safeguarding & Under-16s
Fraser Guidelines (UK) — applicable in GCC clinical settings for assessing competence:
- Young person understands advice and consequences
- Cannot be persuaded to inform or involve parents
- Will likely have sex with or without contraception
- Physical/mental health likely to suffer without contraception
- Best interests to provide contraception without parental consent
Safeguarding duty: if coercion, exploitation, or abuse suspected — mandatory reporting regardless of confidentiality. Document concerns thoroughly.
In GCC: local cultural context means parental/guardian involvement often expected — always apply local laws and nursing council guidance alongside clinical frameworks.
PrEP & Contraception Interactions
- PrEP (Pre-Exposure Prophylaxis for HIV): tenofovir/emtricitabine — no known significant interaction with hormonal contraceptives
- Dolutegravir (part of some PrEP regimens): may slightly increase LNG levels — generally not clinically significant
- Women on PrEP still need effective contraception — address both needs
- Consider Cu-IUD: covers both ongoing contraception and provides non-hormonal option
LGBTQ+ Contraception Needs
- Trans men (FtM) on testosterone: fertility may be reduced but not guaranteed — contraception still needed if any chance of pregnancy
- Progestogen-only methods or Cu-IUD preferred (no oestrogen)
- Non-binary individuals: approach sensitively; assess actual anatomical needs
- Same-sex female couples: contraception not required for pregnancy prevention; STI and cervical screening still apply
- Use inclusive, affirming language in consultations
Contraception Near Menopause
- Fertility declines but does not reach zero until confirmed menopause
- Age <50: continue contraception until 2 years after last menstrual period
- Age >50: continue until 1 year after last menstrual period
- FSH level can guide: two FSH measurements >30 IU/L, 6–8 weeks apart, with amenorrhoea >12 months
- Cu-IUD: if in situ at age 40, can remain until natural menopause confirmed (usually until 55)
- LNG-IUS: can serve dual role as HRT progestogen component + contraception
- HRT does NOT provide reliable contraception — must use additional method
Contraception for Women with Disabilities
- LARC methods preferred: remove compliance burden
- COC: may increase VTE risk in wheelchair users / reduced mobility
- DMPA: reduces seizure frequency in epilepsy (additional benefit)
- Mental capacity: assess capacity for each decision; supported decision-making
- Best interests decisions: multidisciplinary, involve carers/family appropriately
- Consider physical ability to use barrier methods or daily pill
- Menstrual management: LNG-IUS or DMPA for amenorrhoea in women with significant disabilities
GCC Context, Cultural Considerations & Exam Preparation
GCC nursing professionals must integrate clinical evidence with local regulatory, cultural, and religious frameworks.
Islamic Perspectives on Contraception
- Most Islamic scholars permit contraception for married couples for spacing or limiting pregnancies, based on maslaha (public benefit) and preventing harm
- Consensus: reversible contraception (pill, IUD, condom) is permissible with mutual spousal consent
- Permanent sterilisation: more controversial — some scholars permit if health indication exists; not generally recommended for convenience alone
- Emergency contraception: generally permitted as prevention rather than abortion (before implantation)
- Abortion: not accepted for contraception purposes; permissible in specific severe circumstances under Islamic law (varies by madhab)
- Nursing consideration: explore patient's religious understanding respectfully; do not assume; involve religious counsel if patient wishes
Contraception Prescribing Patterns in GCC
- UAE & KSA: High OCP use — often prescribed for cycle regulation, dysmenorrhoea, acne — not exclusively for contraception
- Pharmacist dispensing: OCP available without prescription in many GCC countries — lack of formal regulation; patient may not receive full counselling
- IUD insertion: In some GCC countries cultural practice restricts insertion to female gynaecologists only — nursing role = counselling, preparation, assist
- DMPA: widely used; some countries require spousal consent form (controversial)
- Contraceptive implant: growing availability but less familiar to patients — education role key
- Long-acting methods: under-utilised relative to efficacy — nurse-led LARC counselling can improve uptake
Ethical Issues — Domestic Workers & Access
- Domestic workers in GCC may face significant barriers to contraception access: cost, employer control, language, documentation requirements
- Ethical nursing duty: ensure equitable access regardless of employment status or nationality
- Confidentiality: information must not be shared with employer without patient consent
- Power dynamics: assess for coercion; provide information in patient's first language
- Safeguarding: mandatory reporting if domestic abuse or trafficking suspected
Ramadan & OCP Management
- Many women wish to avoid menstruation during Ramadan (prayer obligations) or Hajj
- COC: run packs consecutively without pill-free interval to suppress withdrawal bleed — clinically safe for short periods
- POP: no hormone-free interval — amenorrhoea more likely with desogestrel POP
- Norethisterone 5mg TDS: can be used to delay period (not a contraceptive)
- Fasting and pill timing: advise to take COC/POP at Iftar (breaking fast) to avoid nausea on empty stomach
- Ensure no missed pills if fasting disrupts routine — use phone reminders
DHA / DOH / QCHP / SCFHS Regulatory Standards
- DHA (Dubai Health Authority): nurses must practice within scope; contraception advice within reproductive health nursing scope — refer to physician for prescription
- DOH (Abu Dhabi Department of Health): family planning falls under primary care nursing standards; documentation of counselling mandatory
- QCHP (Qatar Council for Healthcare Practitioners): reproductive health competencies in nursing scope; cultural sensitivity embedded in standards
- SCFHS (Saudi Commission for Health Specialties): women's health nursing exam includes contraception — UKMEC categories, LARC efficacy, EC timing
- All GCC licensing boards: informed consent documentation, patient education records, referral pathways must be followed
GCC Exam Preparation — High-Yield Topics
These topics appear frequently in DHA/DOH/QCHP/SCFHS licensing exams:
- UKMEC categories 1–4 and specific condition–method pairings
- Emergency contraception: Levonelle (72h) vs ellaOne (120h) vs Cu-IUD (>99%)
- LARC efficacy — all >99% typical use; implant vs IUS vs Cu-IUD vs DMPA differences
- Absolute contraindications to combined OCP (UKMEC 4 list)
- Post-partum contraception timing (especially breastfeeding rules)
- Drug interactions — enzyme inducers and hormonal contraception
- Return to fertility: immediate (Cu-IUD, IUS, implant) vs delayed (DMPA)
- DMPA: bone density monitoring, fertility delay, amenorrhoea rate
- Quick Start — when and how to initiate contraception
- Fraser guidelines — competence assessment in under-16s
- Menopause and contraception continuation rules (<50: 2 yrs; >50: 1 yr)
Interactive Contraceptive Method Selector
Enter patient profile to generate personalised method recommendations with UKMEC grading. For educational use — always apply full clinical assessment.